Assessing the Use of 18F-Fluoromisonidazole FMISO PETMRI Imaging to Study Malignant Brain Tumors

What this Trial Is About

Researchers are evaluating the use of F-fluoromisonidazole FMISO combined with PETMRI imaging to study malignant brain tumors. This phase II trial aims to determine how well FMISO PET and MRI measures can be obtained, and whether MRI contrast-enhancement and hypoxic volume can distinguish between true tumor progression and immunotherapy-related pseudoprogression in glioblastoma patients. The study also assesses the reproducibility of FMISO PET imaging and the feasibility of image co-registration over time. Participants receive FMISO through an intravenous injection and undergo dynamic PETCT or PETMRI imaging for about 120 minutes starting shortly before the injection, followed by a static scan approximately 90 minutes post-injection lasting 20 to 40 minutes. A retest scan is performed within 7 days, and up to two additional scans may be done at intervals of at least 4 weeks. Supplemental oxygen may be given to enhance MRI signals. After these diagnostic scans, participants are monitored for up to five years. During the study, participants undergo multiple imaging sessions including PET, CT, and MRI scans to assess tumor oxygen levels and brain function. Researchers measure imaging features such as hypoxic volume and MRI contrast enhancement. Safety and technical feasibility are evaluated throughout the study and long-term follow-up occurs for up to five years. This comprehensive imaging approach helps researchers understand tumor behavior and treatment response in patients with malignant brain tumors.

Feasibility of FMISO in Brain Tumors